News
LEXXW
--
0.00%
--
Lexaria Announces Cancellation of Options
(via TheNewswire)
TheNewswire.ca · 20h ago
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program
ACCESSWIRE · 1d ago
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
(via TheNewswire)
TheNewswire.ca · 2d ago
Lexaria Bioscience To Begin Applied Research And Development Programs Planned In 2021
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, will begin important new applied research and development
Benzinga · 04/06 11:10
Lexaria Bioscience Announces Results From Stability Testing; Says DehydraTECH CBD-Beverage Demonstrates 93.4% Potency One Year After Production
DehydraTECHTM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution
Benzinga · 03/24 11:08
Lexaria Bioscience Highlights Progress In Hypertension Studies, Says All Five Studies Examining DehydraTECHTM CBD For Hypertension Are Underway
Five studies underway to examine DehydraTECHTM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or
Benzinga · 03/15 11:09
Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast
Newsfile · 01/28 15:09
BRIEF-NeutriSci And Lexaria Bioscience Enter Global Licensing Agreement
* NEUTRISCI AND LEXARIA BIOSCIENCE ENTER GLOBAL LICENSING AGREEMENT
Reuters · 02/26/2018 13:36
Webull provides a variety of real-time LEXXW stock news. You can receive the latest news about LEXARIA BIOSCIEN through multiple platforms. This information may help you make smarter investment decisions.